NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Solid TumorHodgkin's LymphomaNHL (Non-Hodgkin Lymphoma)Pancreatic CancerBreast CancerUC (Ureter and Urethera)Advanced CancerMetastatic Cancer

Interventions

DRUG

INCB047986

Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria

DRUG

INCB047986

INCB047986 tablets administered orally at the protocol specified dose and frequency

DRUG

Gemcitabine

Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency

DRUG

nab-paclitaxel

nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency

Trial Locations (3)

Unknown

Atlanta

Nashville

Dallas